| 证券代码：688026 | 证券简称：洁特生物 公告编号：2024-032 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 具体内容详见公司分别于 2024 年 2 月 19 日、2 月 21 日披露的《关于以集中 竞价交易方式回购公司股份暨公司"提质增效重回报"行动方案的公告》（公告编号： 2024-006）、《关于以集中竞价交易方式回购公司股份的回购报告书》（公告编号： 2024-008）。 二、 回购股份的进展情况 广州洁特生物过滤股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/19 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 期限为自公司董事会审议通过回购方案之日起不 | | | 其中拟用于员工持股计划或股权激励的股份回购 | | | 超过 个月；拟用于维护公司价值及股东权益的 12 | | | 股份回购期限为自公 ...

证券代码：688026 证券简称：洁特生物 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 □新闻发布会 投资者关系活动 □媒体采访 业绩说明会 □路演活动 类别 □现场参观 □其他 参与单位名称 通过上证路演中心召开2023年度暨2024年第一季度业绩说明会 时间 2024年4月30日 地点 线上交流 董事长、代理董事会秘书、代理财务总监袁建华，董事、总经理Yuan 上市公司接待人 Ye James，董事、副总经理何静，证券部负责人葛井波，财务部负责 人谢锋 1、问：请问公司的超滤膜项目验证工作进展是否顺利？预计何时能 量产供货？谢谢！ 答：投资者您好，公司超滤膜包产品已进入产品验证阶段，正在请客 户试用验证，相关工作正在顺利推进中。未来顺利达成量产上市条件 时将配合开展相关市场推广。感谢您的关注！ ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2024-031 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于证券事务代表辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）董事会于近日收到证 券事务代表单泳诗女士的书面辞职报告。单泳诗女士因个人原因申请辞去公司证 券事务代表一职，辞职后将不再担任公司任何职务，辞职报告自送达董事会之日 起生效，其负责的工作已完成交接，其辞职不会影响公司相关工作的正常开展。 单泳诗女士在担任公司证券事务代表期间，恪尽职守、勤勉尽责，在公司治 理、信息披露及规范运作等方面发挥了积极的作用，公司及董事会对单泳诗女士 在职期间为公司发展做出的努力和贡献表示衷心感谢！ 公司董事会将根据《上海证券交易所科创板股票上市规则》等相关规定，尽 快聘任符合任职资格的人员担任证券事务代表。 特此公告。 广州洁特生物过滤股份有限公司董事会 2024 ...

民生证券股份有限公司 关于广州洁特生物过滤股份有限公司 首次公开发行股票并在科创板上市 持续督导保荐总结报告书 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"或"本机构"） 作为广州洁特生物过滤股份有限公司（以下简称"公司"或"发行人"或"洁特 生物"）首次公开发行股票并在科创板上市的保荐机构，根据《上海证券交易所 科创板股票上市规则》的相关规定，民生证券的持续督导期间为 2020 年 1 月 22 日至 2023 年 12 月 31 日。目前前述持续督导期限已届满，根据《证券发行上市 保荐业务管理办法》的要求，出具本持续督导保荐总结报告书。 一、保荐机构及保荐代表人承诺 （一）保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误 导性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担 法律责任。 （二）本保荐机构及本人自愿接受中国证监会对保荐总结报告书相关事项 进行的任何质询和调查。 （三）本保荐机构及本人自愿接受中国证监会按照《证券发行上市保荐业务 管理办法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 保荐机构名称 | 民生证券股份有限公司 | | --- | ...

1、以 3 票同意，0 票反对，0 票弃权，审议通过了《关于 2024 年第一季度报 告的议案》。 经审核，公司 2024 年第一季度报告的编制和审议程序符合相关法律法规及《公 司章程》等内部规章制度的规定；公司 2024 年第一季度报告的内容与格式符合相 关规定，公允地反映了公司 2024 年第一季度的财务状况和经营成果等事项；报告 编制过程中，未发现公司参与报告编制和审议的人员有违反保密规定的行为；监事 会全体成员保证公司 2024 年第一季度报告披露的信息真实、准确、完整，不存在 任何虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2024-029 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 广州洁特生物过滤股份有限公司（ ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥98,275,342.97, representing a year-on-year increase of 32.30%[3] - Net profit attributable to shareholders was ¥8,178,548.18, marking a significant increase of 192.97% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,238,346.03, up by 142.15% year-on-year[3] - The basic and diluted earnings per share both increased to ¥0.07, reflecting a growth of 216.67%[3] - Net profit for Q1 2024 was ¥8,212,634.21, compared to a net loss of ¥8,741,237.41 in Q1 2023, marking a significant turnaround[24] - Earnings per share for Q1 2024 were ¥0.07, compared to a loss per share of ¥0.06 in Q1 2023[25] - The company reported a gross profit margin of approximately 6.4% for Q1 2024, compared to a negative margin in Q1 2023[24] Cash Flow and Investments - The net cash flow from operating activities was ¥35,304,971.53, showing a slight increase of 7.55%[3] - Cash inflow from operating activities in Q1 2024 totaled ¥144,960,102.81, an increase from ¥113,846,781.35 in Q1 2023[26] - The net cash flow from operating activities for Q1 2024 was $35,304,971.53, an increase from $32,825,677.22 in Q1 2023, reflecting a growth of approximately 4.5%[27] - The total cash outflow from investing activities was $88,945,534.56, down from $114,910,710.57 in the previous year, indicating a reduction of about 22.6%[27] - The net cash flow from investing activities was -$26,370,534.56, an improvement compared to -$44,553,665.62 in Q1 2023, showing a decrease in losses of approximately 40.8%[27] - The cash paid for operating activities was $109,655,131.28, an increase from $81,021,104.13 in Q1 2023, indicating a rise of about 35.4%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,610,526,209.12, a decrease of 0.95% from the end of the previous year[4] - The company reported a total current asset of CNY 744,426,952.14 as of March 31, 2024, a decrease from CNY 770,947,880.57 at the end of 2023, reflecting a decline of approximately 3.43%[18] - The company's cash and cash equivalents amounted to CNY 520,200,418.65, down from CNY 539,133,692.05, indicating a decrease of about 3.38%[18] - Accounts receivable decreased to CNY 106,027,611.95 from CNY 127,541,590.16, representing a decline of approximately 16.93%[18] - Non-current assets totaled CNY 866,099,256.98, slightly increasing from CNY 855,104,330.04, indicating a growth of about 0.12%[19] - The total liabilities decreased to ¥464,849,301.35 in Q1 2024 from ¥468,464,645.23 in Q1 2023[20] - The total equity attributable to shareholders was ¥1,145,020,880.34 in Q1 2024, down from ¥1,156,965,623.98 in Q1 2023[20] Research and Development - Research and development expenses totaled ¥6,497,446.91, which is a decrease of 5.20% compared to the previous year[4] - The proportion of R&D expenses to operating revenue was 6.61%, down by 2.62 percentage points[4] - Research and development expenses for Q1 2024 were ¥6,497,446.91, slightly down from ¥6,854,150.51 in Q1 2023[23] Shareholding Structure - The company reported a total shareholding of 41,072,020 shares by Yuan Jianhua, representing 29.26% of the total shares[10] - JET (H.K.) BIOSCIENCE CO., LIMITED holds 17,547,293 shares, accounting for 12.50% of the total shares[10] - The company has a total of 1,708,861 shares in its repurchase account, which constitutes 1.22% of the total share capital[12] - The top 10 shareholders include several investment firms, with the largest being Yuan Jianhua and JET (H.K.) BIOSCIENCE CO., LIMITED[11] - The company’s shareholding structure indicates a significant concentration of ownership among the top shareholders[10] - The total number of shares held by the top 10 unrestricted shareholders is 77,000,000 shares[11] Legal Matters - The lawsuit involving Guangzhou Baifeier Air Purification Materials Co., Ltd. against Guojiji Intelligent Technology Co., Ltd. has a disputed amount of 20,311,900 RMB[12] - The court ruled in favor of Guojiji Intelligent, ordering the return of 20,311,900 RMB plus interest of 1,667,889.10 RMB to Baifeier[12] - The company is currently involved in an appeal process regarding the court's decision in the aforementioned lawsuit[12] - The company has fully provided for bad debts related to prepayments to Shandong Darong amounting to CNY 7,533,582.08 and inventory write-downs of CNY 3,208,618.86 for PTFE composite mask non-woven fabric[13] - The company is involved in multiple legal disputes, including a case with Shandong Darong involving CNY 10,866,391.80 and a case with Jinbang Holdings involving CNY 12,199,190[14][16] - The company has recorded a provision for bad debts of CNY 5,381,000 related to the dispute with Shanghai Deyou, with a claim amount of CNY 18,441,691.80[16] Accounting and Reporting - The company did not apply new accounting standards for the first quarter of 2024, maintaining consistency in financial reporting[28] - The impact of exchange rate changes on cash and cash equivalents was -$1,190,911.91, slightly worse than -$1,083,213.40 in Q1 2023[27]

广州洁特生物过滤股份有限公司 独立董事关于公司第四届董事会第八次会议 相关事项的独立意见 根据中国证监会《上市公司独立董事管理办法》《上海证券交易所科创板股 票上市规则》及《公司章程》等有关规定，我们作为广州洁特生物过滤股份有限 公司（以下简称"公司"）独立董事，本着对公司、全体股东负责的态度，基于 独立、客观、审慎的原则，现就公司第四届董事会第八次会议审议的相关事项发 表如下独立意见： 公司本次出租生产场所有利于提高公司资产使用效率并为公司带来一定收 益，符合公司发展需要。公司董事会在审议《关于出租生产场所暨关联交易的议 案》时，关联交易决策及表决程序符合《上海证券交易所科创板股票上市规则》 《公司章程》的有关规定，遵循了客观、公平、公正的原则，价格公允、合理， 不存在损害公司及全体股东利益的情形。因此，我们同意本次出租生产场所暨关 联交易的事项。 广州洁特生物过滤股份有限公司 独立董事：刘志春、洪炜、刘佳 2024 年 4 月 26 日 1 一、 关于公司 2024 年第一季度报告的独立意见 我们认为，公司严格按照《证券法》《上海证券交易所科创板股票上市规则》 等有关规定，编制了 2024 年第一季度报告 ...

Investment Rating - The report assigns a "Buy" rating for the company, Jiet Bio (688026), marking its first coverage [1]. Core Insights - The company is actively advancing its fundraising projects and enhancing its proprietary brand, with a focus on expanding into the medical consumables and equipment sectors [8][20]. - Despite a challenging market environment, the company aims to increase its market share through improved product quality and brand recognition, particularly in the domestic market [20]. Financial Performance Summary - In Q4 2023, the company achieved a revenue of 133 million yuan, representing a year-on-year increase of 3.03% and a quarter-on-quarter increase of 0.34%. The net profit attributable to shareholders was 21 million yuan, up 885.76% year-on-year and 89.35% quarter-on-quarter [4]. - For the full year 2023, the company reported a total revenue of 463 million yuan, a decline of 24.06% year-on-year, and a net profit of 35 million yuan, down 60.34% year-on-year [16][17]. - The gross profit margin for 2023 was 30.62%, a decrease of 1.22 percentage points compared to the previous year [16]. Segment Performance - The liquid handling segment generated revenue of 274 million yuan, down 33.51% year-on-year, with a gross margin of 30.23% [17]. - The biological culture segment reported revenue of 157 million yuan, a slight decline of 2.63% year-on-year, with a gross margin of 39.08% [17]. - The instruments and other segment saw revenue drop to 18 million yuan, down 39.83% year-on-year, with a negative gross margin of -4.47% [17]. Future Projections - Revenue forecasts for 2024, 2025, and 2026 are projected at 523 million yuan, 630 million yuan, and 811 million yuan, respectively, with corresponding net profits of 48 million yuan, 65 million yuan, and 84 million yuan [11][20]. - The company is expected to improve its price-to-earnings (P/E) ratio from 68.96 in 2023 to 17.49 by 2026, indicating a potential for growth and investment attractiveness [11][20].

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2024-028 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2024 年 4 月 30 日（星期二）上午 11:00-12:00 ● 会议召开地点： 上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络文字互动 ● 投资者可于 2024 年 4 月 23 日（星期二）至 4 月 29 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jetzqb@jetbiofil.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 广州洁特生物过滤股份有限公司（以下简称"公司"）已于 2024 年 4 月 20 日发布公司 2 ...

公司盈利预测及估值 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 610 463 539 634 746 增长率 yoy% -29% -24% 16% 18% 18% 净利润（百万元） 88 35 56 69 86 增长率 yoy% -49% -60% 61% 23% 24% 每股收益（元） 0.62 0.25 0.40 0.49 0.61 每股现金流量 1.18 0.96 0.78 0.99 1.39 净资产收益率 8% 3% 5% 6% 7% P/E 15.7 39.5 24.6 19.9 16.1 P/B 1.2 1.2 1.2 1.1 1.1 备注：股价信息截止时间 2024 年 4 月 20 日 基本状况 总股本(百万股) 140 流通股本(百万股) 140 市价(元) 9.80 市值(百万元) 1,376 流通市值(百万元) 1,374 分析师：祝嘉琦 电话：021-20315150 分析师：谢木青 Email：xiemq@zts.com.cn 执业证书编号：S0740523080002 股价与行业-市场走势对比 相关报告 2 洁特生物公司点评：业绩符合预期 ...